Brian Lumpkin, MD
Family Medicine · Muncie, INNPI 1710976527
Payments from drug & device makers
Across 522 payments — averaging $15.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- Novo Nordisk$1K
- Lilly USA, LLC$901
- Pfizer$607
- Novartis$520
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,97998%
- Education$1292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 64 | $1,294 |
| AbbVie(2 entities) | 104 | $1,161 |
| Novo Nordisk | 61 | $1,028 |
| Lilly USA, LLC | 69 | $901 |
| Pfizer | 37 | $607 |
| Novartis | 30 | $520 |
| GSK | 24 | $294 |
| Amgen(2 entities) | 14 | $284 |
| Boehringer Ingelheim | 12 | $260 |
| Bayer | 10 | $200 |
| Merck | 15 | $196 |
| Astellas Pharma US Inc | 9 | $169 |
| Sanofi-aventis U.S. LLC | 8 | $125 |
| Exact Sciences | 7 | $106 |
| Johnson & Johnson(2 entities) | 7 | $104 |
| E.r. Squibb & Sons, L.L.C. | 6 | $90 |
| Kowa Pharmaceuticals America, Inc. | 7 | $85 |
| Abbott | 5 | $81 |
| Arbor Pharmaceuticals, Inc. | 1 | $81 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $73 |
| Stryker | 1 | $56 |
| Seqirus USA Inc | 3 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $46 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Phathom Pharmaceuticals, Inc. | 4 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Medicure Pharma Inc. | 2 | $28 |
| Daiichi Sankyo Inc. | 2 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Axonics, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Medtronic | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Hologic Sales And Service, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$118
How this compares
$8,108 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 79 | $92,713 |
| OzempicSemaglutide | 43 | $79,134 |
| JardianceEmpagliflozin | 61 | $77,789 |
| TrulicityDulaglutide | 25 | $65,532 |
| FarxigaDapagliflozin Propanediol | 54 | $65,024 |
| EntrestoSacubitril/Valsartan | 31 | $36,749 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $36,248 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 76 | $24,193 |
| JanuviaSitagliptin Phosphate | 22 | $23,918 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $19,004 |
| MyrbetriqMirabegron | 26 | $18,980 |
| XareltoRivaroxaban | 21 | $18,599 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $12,802 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 37 | $8,131 |
| Memantine Hcl ErMemantine Hcl | 35 | $5,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $607 | $116,906155 claims |
| Novo NordiskOzempic | $1,028 | $79,13443 claims |
| Boehringer IngelheimJardiance | $260 | $77,78961 claims |
| Lilly USA, LLCTrulicity | $901 | $65,53225 claims |
| AstraZenecaFarxiga | $1,294 | $65,02454 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $294 | $57,18181 claims |
| NovartisEntresto | $520 | $36,74931 claims |
| MerckJanuvia | $196 | $23,91822 claims |
| Astellas Pharma US IncMyrbetriq | $169 | $18,98026 claims |
| Johnson & JohnsonXarelto | $104 | $18,59921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Muncie
- Jonathan ConditMuncie$1.6M
- Jeffrey HiltzMuncie$177K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.